Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
Mené sur 25 patients atteints d'un cancer avec métastases distantes isolées (durée médiane de suivi : 17,5 mois), cet essai de phase II évalue, du point de vue de la survie globale, du contrôle de la maladie et de la toxicité, l'intérêt de combiner une chimiothérapie concomitante à base de sunitinib avec une radiothérapie hypofractionnée guidée par l'image
Background : Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases. Methods : Twenty five patients with oligometastases, defined as 1–5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1–28) and IGRT 50 Gy (days 8–12 and 15–19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months). Results : The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests. Conclusions : Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases.